Actinogen Medical Limited (AU:ACW) has released an update.
Actinogen Medical Limited, an ASX-listed biotech firm, is advancing Xanamem, a novel therapy for neurological disorders including Alzheimer’s Disease and Depression, with promising trial results and an anticipated interim analysis by mid 2025. The company is embracing digital communication, urging shareholders to attend the forthcoming Annual General Meeting on November 14, 2024, and to update their contact preferences online for receiving electronic documents, as hard copies will only be mailed upon request.
For further insights into AU:ACW stock, check out TipRanks’ Stock Analysis page.
